SEC Form 10-K filed by Natera Inc.

Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

Extensive pan-cancer validation data from over 3,000 plasma samples to be presented at ASCO Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States. This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In this clinical validation study of more than 3,000 samples from multiple cancer types – including breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinom

Data spans immunotherapy (IO) response prediction and genomic landscaping in colorectal cancer (CRC), breast cancer, and gynecological cancers Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL. Highlights from AACR include: An oral presentation titled "Large-scale Genomic Profiling of Colorectal Cancer" from an exploratory analysis examining the characteristics of the mutational landscape of CRC and patterns across clinical and molecular subgroups. The study was performed using

First-of-its-kind prospective trial evaluates the association between dd-cfDNA and clinical outcomes in heart transplantation using Prospera™ Heart with Donor Quantity Score (DQS) Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as measured by Prospera Heart with DQS, are associated

RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00